Efficacy of antiviral agents against omicron subvariants BQ. 1.1 and XBB
M Imai, M Ito, M Kiso, S Yamayoshi… - … England Journal of …, 2023 - Mass Medical Soc
New England Journal of Medicine, 2023•Mass Medical Soc
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to
become a physician, build your knowledge, lead a health care organization, and advance your
career with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to
become a physician, build your knowledge, lead a health care organization, and advance your
career with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
Antiviral Agents and Omicron BQ.1.1 and XBB
Neither bebtelovimab nor any mAb combinations tested neutralized the SARS-CoV-2 omicron subvariants BQ.1.1 and XBB, but remdesivir, molnupiravir, and nirmatrelvir were efficacious against both in vitro.
The New England Journal Of Medicine